Neil Mathews

Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-β Type I Receptor Inhibitors

Françoise Gellibert, James M. Woolven, Marie-Hélène Fouchet et al. · Journal of Medicinal Chemistry · 2004 · 217 citations · Full text

Discovery of 4-{4-[3-(Pyridin-2-yl)-1<i>H</i>-pyrazol-4-yl]pyridin-2-yl}-<i>N</i>-(tetrahydro-2<i>H</i>- pyran-4-yl)benzamide (GW788388):  A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor

Françoise Gellibert, Anne‐Charlotte de Gouville, James M. Woolven et al. · Journal of Medicinal Chemistry · 2006 · 102 citations · Full text

Immunology, Receptor Inhibitor, Pharmacotherapy +19

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein

John P. DeVincenzo, Dereck Tait, John Efthimiou et al. · Antimicrobial Agents and Chemotherapy · 2019 · 84 citations · Full text

State of the Art in Respiratory Syncytial Virus Drug Discovery and Development

G. Stuart Cockerill, James A. D. Good, Neil Mathews · Journal of Medicinal Chemistry · 2018 · 71 citations

Viral Replication, Respiratory Syncytial Virus, Medicine +11

Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion

G. Stuart Cockerill, Richard Angell, Alexandre F. Bedernjak et al. · Journal of Medicinal Chemistry · 2021 · 66 citations · Full text